Anteris Technologies Global Corp. (AVR)
NGM · Healthcare · Medical Instruments & Supplies
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
About Anteris Technologies Global Corp.
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Quarterly Financials
| Metric | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Gross Profit | ||||
| Operating Income | ||||
| Net Income | ||||
| Diluted EPS | $-0.61 | $-0.58 | $-0.62 | $-0.28 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 3.2M | 2.7M | ||
| Gross Profit | 298K | 877K | ||
| Operating Income | -31.5M | -46.7M | ||
| Net Income | -30.6M | -46.0M | ||
| Diluted EPS | $-2.26 | $-2.94 | $-3.77 | $-2.55 |